Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Essential medicines for universal health coverage – Authors’ reply

The letter from Tetsuya Tanimoto and colleagues raises important questions that deserve a response. First, the WHO Member State Mechanism recommended in November, 2016, that the term counterfeit no longer be used to refer to quality-compromised medical products.1 The unwieldy term substandard, spurious, falsely labelled, falsified, counterfeit medical products, has been simplified to substandard and falsified medical products. In the case presented by Tanimoto and colleagues, the product appears to have been falsified.